IMP3 and neoplasm: In this analysis, adjusting for age, gender, tumor size, tumor multiplicity, tumor stage and grade, and smoking history, the IMP3 status in patients with non-muscle-invasive urothelial carcinomas was still independently related to the disease-free survival (hazard ratio (HR): 2.52; 95% confidence interval (CI), 1.39–4.56; P = .002), progression-free survival (HR: 5.19; 95% CI, 1.54–17.46; P = .008) and metastasis-free survival (HR:4.87; 95% CI, 1.08– 22.02; P = .040) rates.